BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology roots with potentially its first commercial cancer drug. Yet, to Chief Commercial Off…
Read guide →